Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 121

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Myasthenia gravis

Not recruiting

Study on the Effectiveness and Safety of Batoclimab for Adults with Generalized Myasthenia Gravis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on the Safety and Efficacy of Linsitinib for Patients with Active, Moderate to Severe Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Linsitinib
  • Sponsor:Sling Therapeutics Inc.

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

HIV infection

Not recruiting

Study Comparing Bictegravir/Lenacapavir to Current Therapy in People with HIV-1 Who Are Successfully Treated

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Rhinitis allergic

Not recruiting

Study on the Effectiveness of Intralyphatic Immunotherapy with Vitamin D for Patients with Allergic Rhinitis Using Phleum Pratense and Colecalciferol

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Colecalciferol
  • Sponsor:Karolinska Institutet
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

C3 glomerulopathy

Not recruiting

Study Comparing Aliskiren and Enalapril for Patients with C3 Glomerulopathy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Aliskiren
  • Sponsor:Region Skane

Study of G1XCGD Lentiviral Vector in Patients with X-Linked Chronic Granulomatous Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Autologous Cd34+ Cells Transduced With The G1Xcgd Lentiviral Vector Containing The Human Cybb Gene
  • Sponsor:Genethon

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.